Dear Friends, Dear Colleagues
On behalf of the Research Centre of Respiratory Diseases (CEPR- UMR INSERM 1100), the Laboratory of Excellence (LabEx) “MAbImprove”, the GDR 3260 “Antibodies and therapeutic targeting”, the Grant Research program ARD2020 “Biotherapeutics” (Région Centre-Val-de-Loire), we are delighted to announce that the first congress on “Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current challenges and perspectives“ will be held in Tours from the 31st of March to the 1st of April 2016. Therefore, we would like to take the present opportunity to invite you to join us for that meeting.
Monoclonal antibodies are approved therapeutics to treat various affections and have a tremendous opportunity to benefit to patient with lung diseases, which continue to represent a significant unmet medical need. As a matter of fact, several of them have reached market approval over the past few years.
With the Scientific Committee, we built an ambitious and unique program illustrating the variety of monoclonal antibodies, either already on the market or currently in development in respiratory diseases. We will also discuss during this meeting strategies to choose the optimal drug format, the best route of administration and relevant experimental models to validate the novel monoclonal antibody candidates. During this day and half congress, we will bring together scientific from both academia and industry, and clinicians from all over the world, in order to lead lively and interactive debates. The congress will take place in the modern “Vinci International Congress Centre” strategically located near the TGV fast train station, in the heart of Tours.
We are looking forward to welcoming and hosting you in Tours during spring 2016, and sincerely hope that you will join us to make this endeavour a success.
The Scientific Committee
